about
Telomeres and telomerase as therapeutic targets to prevent and treat age-related diseasesMissing Cells: Pathophysiology, Diagnosis, and Management of (Pan)Cytopenia in ChildhoodImmunosuppressive therapy for transplant-ineligible aplastic anemia patients.LC-MS/MS detection of increased androstenedione levels in patients receiving danazol therapyModelling Fanconi anemia pathogenesis and therapeutics using integration-free patient-derived iPSCsTherapeutic effect of androgen therapy in a mouse model of aplastic anemia produced by short telomeresAntibodies in the treatment of aplastic anemia.Telomere-driven diseases and telomere-targeting therapies.Predictors of early mortality after rabbit antithymocyte globulin as first-line treatment in severe aplastic anemia.Outcome of a novel immunosuppressive strategy of cyclosporine, levamisole and danazol for severe aplastic anemia.Therapy for aplastic anemia.Costs and consequences of immunosuppressive therapy in children with aplastic anemia.Analysis of allogeneic hematopoietic stem cell transplantation with high-dose cyclophosphamide-induced immune tolerance for severe aplastic anemia.A promising immunosuppressive strategy of cyclosporine alternately combined with levamisole is highly effective for moderate aplastic anemia.Telomere elongation and clinical response to androgen treatment in a patient with aplastic anemia and a heterozygous hTERT gene mutation.
P2860
Q26747735-E60335D4-9B19-4B5E-BFBA-6A04E2AD501CQ26798389-00A553C1-757E-4674-8314-404600EB1DE7Q33419679-D468551D-770B-44C9-8030-5BC9B25103C9Q34476353-60EF52F0-9117-4C02-8711-91B048EDDE41Q34918292-EB6E04B1-4D66-42D9-9E8E-20EB138C51E7Q36115642-D72FAAF0-ED86-45B4-A220-8064BA81C44FQ37981576-B76D4BC0-55B5-489C-B2BF-6DE59DBD6CE9Q39158816-ECB301E9-4375-4702-B497-07BD75C16212Q40090645-72E555DA-A38F-44E1-9B00-935DFCB7C1F7Q41671706-AF5EABFC-BFBA-4724-BA90-56315CF5E981Q41992063-790756C8-8DA5-4AE1-9718-F2AE1B379296Q42743020-13E6881A-ACF5-4CB2-90C0-B4A2350B64DCQ47987154-72824659-0658-4C56-9E15-C091D0B51134Q51815701-D5D61AA5-555F-4F23-9CDB-8ED5C9FBE436Q54519224-250E5A9F-E8FB-45BE-A96E-97CD5C5C9A5E
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Danazol as first-line therapy for aplastic anemia.
@en
Danazol as first-line therapy for aplastic anemia.
@nl
type
label
Danazol as first-line therapy for aplastic anemia.
@en
Danazol as first-line therapy for aplastic anemia.
@nl
prefLabel
Danazol as first-line therapy for aplastic anemia.
@en
Danazol as first-line therapy for aplastic anemia.
@nl
P2093
P2860
P1433
P1476
Danazol as first-line therapy for aplastic anemia.
@en
P2093
Cynthia D Gómez-Ramírez
David Gómez-Almaguer
José Carlos Jaime-Pérez
Luz C Tarín-Arzaga
Perla R Colunga-Pedraza
P2860
P304
P356
10.1007/S00277-011-1163-X
P577
2011-01-29T00:00:00Z